Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Oct 04, 2021 2:16pm
127 Views
Post# 33961640

RE:Line up Mr. Nicolas again!

RE:Line up Mr. Nicolas again!

I'd agree. The dataset will be small. It's likely going to be hard to draw firm conclusions. I think colour adds a lot in those circumstances.


Wino115 wrote: Ok, looks like we need another talking head engagement with mass media!  Who's up for it?  /s

I recall some small Canadian firm once also presented it as their "best idea".  We need to line up folks for one a week for next 8 weeks to keep that 4-handle!  On a serious note, I think it would behoove management as they engage with the investigators on Phase 1a that, if warranted, they request they provide some context around whatever results they see. 

Luckily they have one of the top oncology clinics leading the trial and I've compared their enrolled clinical trials to some others and they are multiples ahead in how many they offer (I guess given the size of the staff).  So they are perfect doctors to compare and contrast TH1902 at this point versus their previous experiences.  I hope they get Dr. Meric-Bernstam in that PR so whomever is looking at investing and reading on the data can understand it better - regardless if it's just safety and MTD or all that plus a bit of POC or efficacy tidbits.  They need to move the program understanding to another level once that hard data is available. 



 

<< Previous
Bullboard Posts
Next >>